ADVA
ADVA (FSE: ADV) today announced that BMC TV deployed its FSP 150 Carrier Ethernet technology to transport coverage of the Paralympic Games from Tokyo to London. The robust, low-power solution empowered BMC TV to cost-effectively provide highly reliable services, enabling hundreds of hours of live broadcasting on high-definition television and online streams. The close support of ADVA’s team, together with the ease of use of its FSP 150 device, helped to ensure the success of the project. Fiber optic solutions provider Fibre Technologies also played a key role.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005059/en/
“We’re proud to have helped bring high-quality coverage of the Paralympics to a UK audience of over 20 million. By harnessing ADVA’s edge Ethernet equipment, we were able to maintain superb network uptime and ensure an exceptional viewer experience,” said Tim Horsfield, director, BMC TV. “We were very impressed with how straightforward ADVA’s solution was to deploy. It also simplifies operations by using established OAM procedures, while its fanless design and low power consumption help to minimize carbon footprint. What’s more, ADVA’s team was always on hand to lend their support and expertise.”
Using the ADVA FSP 150-XG108 Series of Layer 2 service demarcation and aggregation devices, BMC TV was able to provide highly reliable and cost-effective broadcast services. This allowed Channel 4, one of Britain’s biggest television networks, to deliver a rich and immersive viewing experience with every sport at the Tokyo 2020 Paralympic Games covered live and in full. The ADVA FSP 150-XG108 Series enabled BMC TV to efficiently aggregate 1Gbit/s services into 10Gbit/s wavelengths. With its small footprint, redundant power supply and hardware-assisted synchronization, the solution is optimized for cost-sensitive high-bandwidth edge applications.
“The Tokyo Paralympics entertained and inspired millions of viewers. That’s why enabling BMC TV to transmit comprehensive coverage of the games was so rewarding for our team. Our technology and support were key to making this project a major success,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our solution offers advanced demarcation and aggregation capabilities alongside a rich feature set, including hardware-assisted synchronization and zero-touch provisioning for quick and easy service activation. Once again, our FSP 150 technology has shown itself to be in a class of its own for fast and seamless deployment of cost-sensitive Carrier Ethernet services.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About BMC TV
BMC TV are Media Moving experts™. Specialists in IP transport of Broadcast Media over Fibre, Satellite and the Cloud. BMC TV helps broadcasters with connectivity solutions for sports, news and broadcast special events and to deliver this content in multiple formats, to multiple destinations, all around the world. www.bmcuk.tv .
About FTL
Fibre Technologies Ltd (FTL) based in Berkshire, are a highly accredited, multi division, solutions integrator, who specialise in providing the best possible solutions using the latest technology from their chosen partners. They are a financially independent company with a customer base spanning Telco’s, ISP’s, MSP’s, Mod/Government, Education, Industrial and enterprise clients. www.fibre.co.uk .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005059/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom